Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
about
Understanding and altering cell tropism of vesicular stomatitis virusTargeting pediatric cancer stem cells with oncolytic virotherapyNeuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytesInduction of antiviral genes by the tumor microenvironment confers resistance to virotherapyProgress of oncolytic viruses in sarcomas.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Mood stabilizers inhibit cytomegalovirus infection.N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cellsSTAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.Oncolytic Immunotherapy for Treatment of Cancer.Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumorsOvercoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitorsInterferon-Mediated Tumor Resistance to Oncolytic Virotherapy.Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma.Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activityFaster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma.Panorama from the oncolytic virotherapy summit.Using targeted virotherapy to treat a resistant Ewing sarcoma model: from the bedside to the bench and back.Tumor Restrictions to Oncolytic Virus.Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
P2860
Q27687067-46F431F1-8BDA-4A34-B044-02B2019B3018Q34262327-EF1423EE-BEC7-4BFA-A21D-276784469895Q36667968-054648C8-8E76-4012-96E6-D068E1010797Q36751597-44BC9A94-0EED-4E48-9C2F-51C54D83E61BQ36911654-46678095-CA3D-458F-AC07-CC59500E73FCQ37076976-4DB16D14-025D-490A-A1BC-12E745017126Q37982449-3D28950D-0B0F-447E-A00E-74F76123D5FBQ38025696-EF3B9DB1-C802-47BE-BF7D-8EE7980BCF66Q38237657-1514A3A0-C696-4626-9532-F7301070E0FBQ38744376-69CC2967-0D7D-4165-9624-20B27B41A9DBQ38746434-43D5EE04-62D6-4982-AD60-9F67D3D62BC0Q38793802-94B458C1-9BA8-4BC8-BF5F-F14BCEC7023CQ38848223-6D78495C-1F55-4F60-A225-3A400B1BC496Q38860287-8E91C853-B47B-42F8-B634-949630BA08ACQ38886667-5F23D26F-6CFB-4092-9A08-3B36644A1F15Q39096636-76D228C7-79AA-4FEE-A6B0-077BBADD2663Q39109430-F0088D7A-DF3C-4AC8-9F03-3C59CD40B92EQ39213379-FE8365BD-A8E0-4F63-9990-6C4C98939191Q39224943-8E9C6E92-9504-4422-97AD-DB0977978058Q39354544-CDEAB52E-B4F9-4D4B-9474-0B8E01D834C3Q40177986-B7FC2A7E-C28C-4EE7-AD28-7A672F6424F7Q40465319-3437402E-5611-4FB7-92EA-791AC1F4B3BFQ41770092-A973381A-DD0B-4C0D-8DE8-506EA73067C7Q41903358-69EBB954-CD4B-4C5F-826E-3A1156D97013Q42010342-D4DFF509-05D3-4FAA-A6AE-5A7D41964AE1Q42934744-535F3132-44F6-4423-9D15-82C69CBDF998Q51287424-93C9C63F-395B-4F6A-9340-3BD51FA41ACCQ51846287-D12BF3A6-039D-4E6D-8AE7-33A982E0B273Q58729482-67A51327-FACC-4B7F-AC5D-BC41437C38EB
P2860
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Vesicular stomatitis virus has ...... blocking interferon pathways.
@en
type
label
Vesicular stomatitis virus has ...... blocking interferon pathways.
@en
prefLabel
Vesicular stomatitis virus has ...... blocking interferon pathways.
@en
P2860
P356
P1433
P1476
Vesicular stomatitis virus has ...... blocking interferon pathways.
@en
P2093
Anthony N van den Pol
Justin C Paglino
P2860
P304
P356
10.1128/JVI.00723-11
P407
P577
2011-07-06T00:00:00Z